Welcome to our dedicated page for SenesTech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
SenesTech has announced an At The Market (ATM) offering of up to $843,069 of common stock through H.C. Wainwright & Co. The offering will be conducted on the Nasdaq Capital Market (SNES) at prevailing market prices, with Wainwright receiving a 3.0% commission on gross sales.
Key details of the offering:
- Last reported stock price: $3.96 per share (June 20, 2025)
- Current market cap (non-affiliate): $8.56 million based on 2,015,291 shares
- Previous sales under Form S-3: $2,011,926.24 in past 12 months
The company specializes in fertility control products for pest management, with two main product lines: ContraPest and Evolve. Recent developments include the January 2024 launch of Evolve Rat and May 2024 launch of Evolve Mouse, both classified as minimum risk pesticides. ContraPest is registered in all 50 states, while Evolve Rat is authorized in 48 states and Evolve Mouse in 36 states.
SenesTech has filed a prospectus for the resale of up to 1,517,608 shares of common stock, comprising 1,498,872 Inducement Shares (exercise price $2.90) and 18,736 Placement Agent Shares (exercise price $3.625). The shares are issuable upon exercise of outstanding warrants.
Key highlights:
- Trading on Nasdaq Capital Market under symbol SNES with last reported price of $3.40 (June 13, 2025)
- Company will receive proceeds from cash exercises of warrants but not from cashless exercises
- Selling stockholders bear selling expenses while company covers registration costs
SenesTech's business focuses on rodent population control through fertility management products ContraPest and Evolve. The company expects continued operating losses and faces risks including product commercialization challenges, market acceptance, and maintaining Nasdaq listing compliance. Forward-looking statements indicate plans for international expansion and using warrant proceeds for R&D, working capital, and potential strategic acquisitions.
The SEC has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 4:00 P.M. The registration statement was filed under file number 333-288097.
Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their intended securities offering as outlined in the registration statement.
This development is significant for investors as it means:
- SenesTech can now legally begin selling the registered securities to the public
- The company has satisfied SEC review requirements
- The registration statement contains complete and accurate information according to SEC standards
The Securities and Exchange Commission has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 5:00 P.M. The registration statement was filed under file number 333-286955.
Form S-3 is a simplified security registration form used by companies that have already met specific reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their planned securities offering as outlined in the registration statement.
This is a significant development for SenesTech (SNES) as it:
- Allows the company to access the public markets for capital raising
- Provides flexibility to issue various types of securities
- Enables shelf offerings for up to three years from the effective date